ducovest

LIFE-B:CA:TSX-Evolve Global Healthcare Enhanced Yield Fund UnHedged Units (CAD)

ETF | Others |

Last Closing

CAD 24.48

Change

-0.07 (-0.29)%

Market Cap

N/A

Volume

300.00

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Currency: CAD

Country : Canada

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-27 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XEF-U:CA iShares Core MSCI EAFE IMI Ind..

N/A

 CAD 6.19B
XEQT:CA iShares Core Equity Portfolio

N/A

 CAD 5.85B
CASH:CA GLOBAL X HIGH INTEREST SAVINGS..

N/A

 CAD 5.48B
PHYS-U:CA Sprott Physical Gold Trust

N/A

 CAD 4.76B
XUS-U:CA iShares Core S&P 500 Index ETF

N/A

 CAD 4.54B
HXT-U:CA Global X S&P/TSX 60 Index ETF

N/A

 CAD 3.92B
CEF-U:CA Sprott Physical Gold and Silve..

N/A

 CAD 3.78B
PSLV-U:CA Sprott Physical Silver Trust

N/A

 CAD 3.29B
ZMMK:CA BMO Money Market Fund ETF Seri..

N/A

 CAD 2.98B
NSCB:CA NBI Sustainable Canadian Bond ..

N/A

 CAD 2.78B

ETFs Containing LIFE-B:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 2.90% 24% F 30% F
Dividend Return 7.40% 89% A- 89% A-
Total Return 10.30% 37% F 37% F
Trailing 12 Months  
Capital Gain 2.90% 24% F 30% F
Dividend Return 7.40% 89% A- 89% A-
Total Return 10.30% 37% F 37% F
Trailing 5 Years  
Capital Gain 6.02% 41% F 45% F
Dividend Return 37.33% 91% A- 91% A-
Total Return 43.35% 63% D 58% F
Average Annual (5 Year Horizon)  
Capital Gain 2.30% 46% F 42% F
Dividend Return 2.74% 48% F 37% F
Total Return 0.44% 75% C 30% F
Risk Return Profile  
Volatility (Standard Deviation) 5.91% 76% C+ 89% A-
Risk Adjusted Return 46.39% 62% D 60% D-
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.